摘要
目的评价IL-2(白细胞介素-2)联合顺铂对比顺铂治疗恶性胸腔积液的有效性及安全性。方法计算机检索Pubmed、The Cochrane Library、Web of Science、Embase、中国知网、维普全文数据库和万方数据库。研究者筛选文献、提取数据并评价文献质量,采用Rev Man 5.3软件进行Meta分析。结果共纳入16项随机对照研究、894例患者。Meta分析结果显示:IL-2联合顺铂治疗恶性胸腔积液的有效率、完全缓解率、生活质量改善率明显高于单独用顺铂。不良反应中IL-2联合顺铂发热发生率高于单独应用顺铂,而胸痛、消化道反应、骨髓抑制的发生率两组比较差异无统计学意义(P>0.05)。结论 IL-2联合顺铂治疗恶性胸腔积液的疗效、生存质量改善均明显优于单独用顺铂,仅发热发生率较单用顺铂高,有一定的临床推广应用价值,但须采取一定的措施预防不良反应的发生。
Objective To evaluate the efficacy and safety of interleukin（IL-2） combined with cisplatin in the treatment of malignant pleural effusion. Methods A computer-based retrieval were made in Pubmed, The Cochrane Library, Web of Science, Embase, CNKI, VIP, and Wanfang database. We screened the literature, extracted data and evaluated the quality of literature. A meta-analysis was undertaken by Rev Man 5.3. Results A total of 16 randomized controlled trials with 894 patients were included. IL-2 combined with cisplatin was higher than cisplatin for treating malignant pleural effusion in the aspects of the response rate, complete response rate, the life quality improvement and fever occurrence rate. IL-2 combined with cisplatin didn＇t increase the incidence rates of pectoralgia, myelosuppression, gastrointestinal（P〈0.05）. Conclusion IL-2 combined with cisplatin can significantly improve the therapeutic effect and the quality of life in patients with malignant pleural effusion than cisplatin, but with higher incidence of fever. It has some clinical application value, but certain measures must be taken to prevent the occurrence of adverse reactions.
出处
《海南医学》
CAS
2017年第5期839-843,共5页
Hainan Medical Journal
基金
国家自然科学基金(编号:8156031188)
